Core Laboratories Crescita futura

Future criteri di controllo 2/6

Core Laboratories prevede che gli utili e i ricavi cresceranno rispettivamente di 17.4% e 3.7% all'anno. Si prevede che l'EPS crescerà di 17.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 14.2% in 3 anni.

Informazioni chiave

17.4%

Tasso di crescita degli utili

17.3%

Tasso di crescita dell'EPS

Energy Services crescita degli utili	17.4%
Tasso di crescita dei ricavi	3.7%
Rendimento futuro del capitale proprio	14.2%
Copertura analitica	Good
Ultimo aggiornamento	04 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year

May 02

Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?

Mar 26

Why We're Not Concerned About Core Laboratories Inc.'s (NYSE:CLB) Share Price

Mar 02

Core Laboratories: EPS Miss, But Beneficial Outlook About Exploration Efforts

Nov 09

Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture

Sep 08

Core Laboratories: 'Spooked The Herd' In June, Things Might Be Looking Up

Aug 16

Core Laboratories Inc.'s (NYSE:CLB) Earnings Haven't Escaped The Attention Of Investors

Jul 05

The Returns On Capital At Core Laboratories (NYSE:CLB) Don't Inspire Confidence

May 25

Previsioni di crescita degli utili e dei ricavi

NYSE:CLB - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	569	47	53	73	3
12/31/2025	556	49	46	62	6
12/31/2024	528	36	39	54	6
9/30/2024	523	26	44	55	N/A
6/30/2024	514	24	30	42	N/A
3/31/2024	511	38	22	33	N/A
12/31/2023	510	37	14	25	N/A
9/30/2023	509	41	9	19	N/A
6/30/2023	510	39	15	25	N/A
3/31/2023	503	24	6	16	N/A
12/31/2022	490	19	15	25	N/A
9/30/2022	487	15	6	19	N/A
6/30/2022	479	9	11	25	N/A
3/31/2022	477	10	21	34	N/A
12/31/2021	470	20	23	37	N/A
9/30/2021	459	31	5	18	N/A
6/30/2021	446	33	15	26	N/A
3/31/2021	443	19	32	44	N/A
12/31/2020	487	-97	45	58	N/A
9/30/2020	530	-101	77	91	N/A
6/30/2020	598	-80	79	96	N/A
3/31/2020	651	-55	66	86	N/A
12/31/2019	668	94	67	90	N/A
9/30/2019	685	92	83	106	N/A
6/30/2019	694	90	82	104	N/A
3/31/2019	700	96	90	114	N/A
12/31/2018	701	80	89	112	N/A
9/30/2018	698	93	98	120	N/A
6/30/2018	678	91	N/A	126	N/A
3/31/2018	661	87	N/A	118	N/A
12/31/2017	648	81	N/A	124	N/A
9/30/2017	627	75	N/A	102	N/A
6/30/2017	608	71	N/A	107	N/A
3/31/2017	598	67	N/A	116	N/A
12/31/2016	590	65	N/A	132	N/A
9/30/2016	628	64	N/A	158	N/A
6/30/2016	682	81	N/A	167	N/A
3/31/2016	738	99	N/A	186	N/A
12/31/2015	798	115	N/A	219	N/A
9/30/2015	893	166	N/A	268	N/A
6/30/2015	972	199	N/A	299	N/A
3/31/2015	1,036	228	N/A	317	N/A
12/31/2014	1,085	257	N/A	303	N/A
9/30/2014	1,083	256	N/A	293	N/A
6/30/2014	1,080	251	N/A	293	N/A
3/31/2014	1,075	247	N/A	296	N/A
12/31/2013	1,074	243	N/A	298	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di CLB ( 17.4% all'anno) è superiore al tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Si prevede che gli utili di CLB ( 17.4% all'anno) cresceranno più rapidamente del mercato US ( 15.4% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di CLB cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di CLB ( 3.7% all'anno) crescerà più lentamente rispetto al mercato US ( 9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CLB ( 3.7% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di CLB sarà basso tra 3 anni ( 14.2 %).

Core Laboratories Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Core Laboratories Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Consensus EPS estimates fall by 14%

Core Laboratories Inc. Provides Consolidated Earnings Guidance for the Fourth Quarter of 2023

Consensus EPS estimates increase by 24%

Recent updates

Now 20% undervalued

Is Core Laboratories (NYSE:CLB) Using Too Much Debt?

Third quarter dividend of US$0.01 announced

Third quarter 2024 earnings: EPS exceeds analyst expectations

Core Laboratories Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Now 20% undervalued after recent price drop

Core Laboratories Inc. to Report Q3, 2024 Results on Oct 23, 2024

Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?

What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E

Investor sentiment deteriorates as stock falls 16%

Second quarter dividend of US$0.01 announced

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Core Laboratories Inc. Approves Cash Dividend, Payable on August 26, 2024

Investor sentiment improves as stock rises 15%

We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt

Core Laboratories Inc. to Report Q2, 2024 Results on Jul 24, 2024

These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong

It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year

First quarter dividend of US$0.01 announced

Core Laboratories Inc. Approves Cash Dividend, Payable on May 28, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Core Laboratories Inc. to Report Q1, 2024 Results on Apr 24, 2024

Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?

Core Laboratories Inc., Annual General Meeting, May 08, 2024

Consensus EPS estimates fall by 14%

Why We're Not Concerned About Core Laboratories Inc.'s (NYSE:CLB) Share Price

Fourth quarter dividend of US$0.01 announced

Full year 2023 earnings: EPS misses analyst expectations

Core Laboratories Inc. Approves Cash Dividend, Payable on March 4, 2024

Core Laboratories: EPS Miss, But Beneficial Outlook About Exploration Efforts

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Core Laboratories Inc. Provides Consolidated Earnings Guidance for the Fourth Quarter of 2023

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 24%

Now 21% undervalued after recent price drop

Core Laboratories Inc. to Report Q3, 2023 Results on Nov 01, 2023

Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture

Core Laboratories: 'Spooked The Herd' In June, Things Might Be Looking Up

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Core Laboratories Inc.'s (NYSE:CLB) Earnings Haven't Escaped The Attention Of Investors

Core Laboratories Inc. Approves to Elect Curtis Anastasio as Class I Director

Core Laboratories Inc. to Report Q2, 2023 Results on Jul 26, 2023

Investor sentiment improves as stock rises 17%